

Sandor Batkai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3289903/sandor-batkai-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

6,467
citations

40
h-index

80
g-index

83
ext. papers

7,492
ext. citations

8.5
avg, IF

5.3
L-index

#	Paper	IF	Citations
79	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.. <i>Cardiovascular Research</i> , 2022 ,	9.9	3
78	Skeletal muscle derived Musclin protects the heart during pathological overload.. <i>Nature Communications</i> , 2022 , 13, 149	17.4	3
77	Telomerase therapy attenuates cardiotoxic effects of doxorubicin. <i>Molecular Therapy</i> , 2021 , 29, 1395-1410	10.7	13
76	AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2923-2935	15.1	11
75	CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 192-201	9.5	25
74	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. <i>European Heart Journal</i> , 2021 , 42, 178-188	9.5	57
73	Preclinical development of a miR-132 inhibitor for heart failure treatment. <i>Nature Communications</i> , 2020 , 11, 633	17.4	59
72	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation</i> , 2020 , 141, 751-767	16.7	27
71	Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. <i>European Heart Journal</i> , 2020 , 41, 3462-3474	9.5	35
70	Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine. <i>Biomolecules</i> , 2020 , 10,	5.9	10
69	Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry. <i>Frontiers in Pharmacology</i> , 2020 , 11, 220	5.6	0
68	Studying Interactions between 2FO-Me-Modified Inhibitors and MicroRNAs Utilizing Microscale Thermophoresis. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 18, 259-268	10.7	2
67	Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212. <i>Scientific Reports</i> , 2019 , 9, 1302	4.9	18
66	Selective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212. <i>Frontiers in Oncology</i> , 2019 , 9, 598	5.3	11
65	TIP30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10018	12	8
64	miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity. <i>Molecular Therapy</i> , 2019 , 27, 17-28	11.7	23
63	Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 78-85	12.3	43

62	Novel insight into arrhythmogenic remodeling: a target for reversal. <i>Hypertension Research</i> , 2017 , 40, 632-634	4.7	
61	Inhibition of the Cardiac Fibroblast-Enriched lncRNA Prevents Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation Research</i> , 2017 , 121, 575-583	15.7	190
60	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. <i>Journal of Translational Medicine</i> , 2017 , 15, 202	8.5	18
59	MicroRNAs in right ventricular remodelling. <i>Cardiovascular Research</i> , 2017 , 113, 1433-1440	9.9	18
58	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , 2016 , 134, 1973-1990	16.7	32
57	Long noncoding RNA Chast promotes cardiac remodeling. <i>Science Translational Medicine</i> , 2016 , 8, 326ra27.5	27.5	250
56	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. <i>Cardiovascular Research</i> , 2016 , 110, 215-26	9.9	49
55	Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1557-71	15.1	75
54	Zinc- α -Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2659-68	12.7	20
53	Osteopontin is indispensable for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. <i>European Heart Journal</i> , 2015 , 36, 2184-96	9.5	95
52	Plasma and tissue homoarginine concentrations in healthy and obese humans. <i>Amino Acids</i> , 2015 , 47, 1847-52	3.5	15
51	Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. <i>Circulation</i> , 2015 , 131, 1071-81	16.7	48
50	Endocannabinoid-mediated modulation of Gq/11 protein-coupled receptor signaling-induced vasoconstriction and hypertension. <i>Molecular and Cellular Endocrinology</i> , 2015 , 403, 46-56	4.4	26
49	Vascular importance of the miR-212/132 cluster. <i>European Heart Journal</i> , 2014 , 35, 3224-31	9.5	64
48	Analytical approaches in microRNA therapeutics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 964, 146-52	3.2	11
47	Trapping of NAPQI, the intermediate toxic paracetamol metabolite, by aqueous sulfide (S ²⁻) and analysis by GC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 963, 99-105	3.2	3
46	MicroRNAs in right ventricular (dys)function (2013 Grover Conference series). <i>Pulmonary Circulation</i> , 2014 , 4, 185-90	2.7	19
45	Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2136-46	15.9	617

44	Clinical evaluation of extracellular ADMA concentrations in human blood and adipose tissue. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 1189-200	6.3	6
43	Nitro-oleic acid and epoxy-oleic acid are not altered in obesity and type 2 diabetes. <i>Cardiovascular Research</i> , 2014 , 102, 517-8	9.9	1
42	MicroRNAs play a role in spontaneous recovery from acute liver failure. <i>Hepatology</i> , 2014 , 60, 1346-55	11.2	62
41	LC-MS/MS and GC-MS/MS measurement of plasma and urine di-paracetamol and 3-nitro-paracetamol: proof-of-concept studies on a novel human model of oxidative stress based on oral paracetamol administration. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 959, 71-81	3.2	6
40	Regulation of cardiac and renal ischemia-reperfusion injury by microRNAs. <i>Free Radical Biology and Medicine</i> , 2013 , 64, 78-84	7.8	47
39	MicroRNA-mediated epigenetic silencing of sirtuin1 contributes to impaired angiogenic responses. <i>Circulation Research</i> , 2013 , 113, 997-1003	15.7	47
38	Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury. <i>Nucleic Acid Therapeutics</i> , 2013 , 23, 344-54	4.8	44
37	Enhanced human tissue microdialysis using hydroxypropyl- β -cyclodextrin as molecular carrier. <i>PLoS ONE</i> , 2013 , 8, e60628	3.7	13
36	MicroRNAs in hypertension: mechanisms and therapeutic targets. <i>Current Hypertension Reports</i> , 2012 , 14, 79-87	4.7	105
35	Peripheral endocannabinoid microdialysis: in vitro characterization and proof-of-concept in human subjects. <i>Analytical and Bioanalytical Chemistry</i> , 2012 , 402, 2727-35	4.4	6
34	Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants. <i>Free Radical Biology and Medicine</i> , 2012 , 53, 1123-38	7.8	95
33	β -Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. <i>British Journal of Pharmacology</i> , 2012 , 165, 2450-61	8.6	29
32	Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. <i>Diabetes</i> , 2012 , 61, 716-27	0.9	178
31	Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 883-884, 161-71	3.2	77
30	The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. <i>Nature Communications</i> , 2012 , 3, 1078	17.4	406
29	A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. <i>British Journal of Pharmacology</i> , 2012 , 165, 2462-78	8.6	78
28	Stable isotope liquid chromatography-tandem mass spectrometry assay for fatty acid amide hydrolase activity. <i>Analytical Biochemistry</i> , 2012 , 421, 699-705	3.1	8
27	Circulating anandamide and blood pressure in patients with obstructive sleep apnea. <i>Journal of Hypertension</i> , 2012 , 30, 2345-51	1.9	26

26	Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2011 , 1811, 706-23	5	118
25	Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. <i>Free Radical Biology and Medicine</i> , 2011 , 50, 179-95	7.8	66
24	Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. <i>Free Radical Biology and Medicine</i> , 2011 , 50, 1368-81	7.8	128
23	CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. <i>British Journal of Pharmacology</i> , 2010 , 160, 657-68	8.6	97
22	Measurement and diagnostic use of hepatic cytochrome P450 metabolism of oleic acid in liver disease. <i>Liver International</i> , 2010 , 30, 1181-8	7.9	7
21	CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. <i>Cardiovascular Research</i> , 2010 , 85, 773-84	9.9	131
20	Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 2115-25	15.1	297
19	Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. <i>Free Radical Biology and Medicine</i> , 2010 , 48, 457-67	7.8	160
18	Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. <i>Chemistry and Biology</i> , 2010 , 17, 1256-66		77
17	Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2953-66	15.9	343
16	CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. <i>PLoS ONE</i> , 2009 , 4, e6409	3.7	43
15	Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 2330-2341	5.6	64
14	Circulating endocannabinoid concentrations during orthostatic stress. <i>Clinical Autonomic Research</i> , 2009 , 19, 343-6	4.3	22
13	Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?. <i>Trends in Pharmacological Sciences</i> , 2009 , 30, 1-7	13.2	115
12	Endocannabinoids and cardiac contractile function: pathophysiological implications. <i>Pharmacological Research</i> , 2009 , 60, 99-106	10.2	43
11	Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 296, H1466-83	5.2	261
10	Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation and cell death. <i>FASEB Journal</i> , 2009 , 23, 617.5	0.9	
9	Peripheral endocannabinoid system activity in patients treated with sibutramine. <i>Obesity</i> , 2008 , 16, 1135-7		14

8	Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. <i>Nature Protocols</i> , 2008 , 3, 1422-34	18.8	540
7	CB1 cannabinoid receptor inhibition: promising approach for heart failure?. <i>Congestive Heart Failure</i> , 2008 , 14, 330-4		20
6	Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. <i>Cell Metabolism</i> , 2008 , 7, 227-35	24.6	246
5	Endocannabinoids and the control of energy homeostasis. <i>Journal of Biological Chemistry</i> , 2008 , 283, 33021-5	5.4	72
4	Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. <i>Hypertension</i> , 2008 , 52, 601-7	8.5	81
3	Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3160-9	15.9	351
2	Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. <i>PLoS ONE</i> , 2008 , 3, e1701	3.7	38
1	The Role of Endocannabinoids and Their Receptors in the Control of Hepatic Functions1091-1103		